system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: PURPOSE, PATIENTS AND METHODS, RESULTS. Meshes: Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols, Bleomycin, Case-Control Studies, Chi-Square Distribution, Cyclophosphamide, Disease-Free Survival, Doxorubicin, Female, Follow-Up Studies, Humans, L-Lactate Dehydrogenase, Lymphoma, Non-Hodgkin, Male, Middle Aged, Multivariate Analysis, Neoplasm Staging, Prednisone, Prognosis, Recurrence, Remission Induction, Retrospective Studies, Risk Factors, Survival Rate, Vindesine.
user
Is the small non-cleaved-cell lymphoma histologic subtype a poor prognostic factor in adult patients? Context: To study the prognostic significance of the small non-cleaved-cell lymphoma (SNCCL) histologic subtype, we compared the outcome of adult patients with SNCCL with that of patients with aggressive lymphoma other than SNCCL by means of two case-controlled studies. We analyzed the results of the doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (ACVBP) regimen used as a reference scheme in our cooperative study group (Groupe d'Etude des Lymphomes de l'Adult [GELA]) in 52 adult SNCCL patients with no bone marrow (BM) or CNS involvement. Forty-five SNCCL patients younger than 60 years could be compared with two separate case-matched groups of patients with aggressive lymphoma other than SNCCL undergoing the same therapeutic regimen. In the first case-controlled study, matching ensured identity of each risk factor of the age-adjusted International Index(ie, Ann Arbor stage, performance status, and lactate dehydrogenase [LDH] level); in the second study, matching was performed according to the number of presenting risk factors (zero, one, two, or three), regardless of their nature. The 5-year overall survival rates were not significantly different between SNCCL and control patients in both case-controlled studies: 48% versus 51% in the first study, and 48% versus 55% in the second study.
assistant
These results support the thesis that in patients with no bone marrow or CNS involvement, the SNCCL histologic subtype does not confer a prognosis worse than that of other aggressive lymphoma.